My neighbor called me last spring, frustrated. She had been prescribed Wegovy by her regular doctor, her insurance denied it, and the out-of-pocket quote at the local pharmacy was $1,400 a month. She asked me which telehealth option was worth trying. I did not have a fast answer. So I spent real time digging into the pricing, pharmacy sourcing, physician models, and shipping logistics for the services people are actually using in 2026. Here is what I found, organized by what different people actually need.
For Budget-First Shoppers on Cash Pay
1. Mochi Health
Compounded semaglutide starts at $99 a month, tirzepatide at $199. What separates Mochi from the cheaper-looking options is that board-certified obesity-medicine clinicians do the evaluations, not just general practitioners clicking through a queue. More monitoring than most cash-pay platforms. Worth it if you want clinical oversight without paying a premium program fee on top of medication costs.
2. MEDVi
Around $179 for the first month, no long-term contracts required. Compounded GLP-1s, straightforward onboarding. Good for someone who wants to test the waters without committing to a 12-month program structure.
3. Eden
Compounded semaglutide at roughly $149 a month cash. Lean on extras, which is either a feature or a drawback depending on how much hand-holding you want.
For People Who Want Branded Meds and Insurance Help
4. PlushCare
Membership runs about $19.99 a month. Same-day visits are genuinely available. PlushCare works with insurance for branded GLP-1s, which matters if your plan covers Wegovy or Zepbound and you just need a prescriber who can actually get you an appointment this week instead of three months from now.
For Transparent Pharmacy Sourcing (Cash Pay)
5. HealthRX
Compounded semaglutide from $99 a month, compounded tirzepatide from $149 a month. Those prices are the actual starting point, not a teaser that assumes quarterly billing or a bundled program fee.
The pharmacy is Manifest Pharmacy in Greer, South Carolina, a 503A compounding facility operating under USP-797 standards with lot-tracking from production through delivery. That level of specificity matters. A lot of telehealth platforms source from unnamed compounding labs and you have no way to verify anything. HealthRX is LegitScript-certified (certificate 50087439), HIPAA compliant, and ships free overnight to all 50 states. A US board-certified physician reviews your intake within about 24 hours.
The trial data the platform cites is real and published: tirzepatide showed roughly 21% average body weight reduction at 72 weeks in SURMOUNT-1; semaglutide showed roughly 15% at 68 weeks in STEP 1. HealthRX references those numbers rather than making independent efficacy claims. That is the honest way to do it.
One honest note: these are compounded medications, not FDA-approved products. That applies to most of the cash-pay options on this list, not just this one.
6. FormBlends
Per-vial pricing is higher than HealthRX. Semaglutide runs around $299, tirzepatide around $349. Ships to 47 states, not all 50. So why is it here?
FormBlends publishes per-product purity testing with actual numbers: HPLC purity percentages, mass spec identity confirmation, endotoxin and sterility results. For buyers who want to read the lab documentation before injecting anything, that transparency is worth a price premium. The platform also carries a broader catalog covering recovery, longevity, and cognitive peptides alongside the GLP-1 offerings, all under the same clinician model. If you want one provider for GLP-1s plus other peptides and you want documented purity data, FormBlends earns the spot. If price per month is the deciding factor, HealthRX wins that comparison cleanly.
For Coaching-Heavy Programs
7. Calibrate
Calibrate pairs a 12-month program with separate medication costs and meaningful coaching infrastructure. It is not cheap. The structure suits someone who has tried GLP-1s before without lifestyle support and wants a more guided framework this time.
8. Found
About $99 a month for the platform, medications billed separately. Coaching is included. Mid-range commitment, decent support layer.
9. Form Health
Premium pricing around $299 a month, plus labs and medications on top. You get both an MD and a registered dietitian on your care team. The most clinically intensive option on this list for someone who wants that level of involvement and can afford it.
For Brand-Name Flexibility and Big-Platform Convenience
10. Hims and Hers
After the Novo Nordisk settlement in March 2026, Hims and Hers shifted away from compounded GLP-1s and now focuses on branded medications. Injectable Wegovy is listed at around $299 a month through the platform, oral options around $249, and Zepbound around $399. With insurance and a savings card, costs can drop to near zero for eligible patients. The name recognition and app experience are strong. Less useful if your insurance covers nothing and you are purely cash-pay shopping on price.
A Few Things Worth Knowing Before You Pick
The FDA sent warning letters to more than 30 telehealth and compounding companies in early 2026. The space is not uniformly regulated. Checking LegitScript certification and identifying the actual dispensing pharmacy by name before you order is not paranoia, it is basic due diligence.
Also, Lilly launched oral orforglipron through LillyDirect around April 2026 at roughly $149 a month. That changes the calculus for people who prefer pills. Worth checking current availability before you default to injections.
None of these services are a substitute for a relationship with your primary care doctor. A telehealth prescriber is a real physician, but they are working from a questionnaire. Disclose everything accurately.
Common Questions
Is compounded semaglutide from a telehealth clinic actually the same drug as Ozempic or Wegovy?
No, and the distinction matters. Compounded semaglutide contains the same active molecule, but it is not manufactured by Novo Nordisk and has not gone through FDA approval as a finished drug product. Quality depends entirely on the compounding pharmacy. Services like HealthRX name their pharmacy outright; others do not, which makes verification much harder before you commit.
Why does HealthRX cost less than FormBlends for what looks like the same medication?
Pricing reflects different overhead models. HealthRX partners with a single named 503A pharmacy, Manifest Pharmacy, and keeps the catalog narrow. FormBlends charges more partly because it publishes detailed per-batch lab documentation, HPLC purity data, mass spec results, and sterility testing, and it stocks a wider peptide catalog. You are paying for documented transparency, not necessarily a better molecule.
If my insurance already covers Wegovy, is there any reason to use one of these telehealth platforms instead of my regular doctor?
Access and speed, mostly. Many primary care offices have months-long waits for new GLP-1 prescriptions or simply are not prescribing them yet. PlushCare offers same-day visits and works directly with insurance for branded GLP-1s, so it can be a faster path to a legitimate prescription even if your long-term plan is to move care back to your own physician.
After the Novo Nordisk settlement in March 2026, can platforms like Hims and Hers still offer compounded semaglutide?
Publicly, Hims and Hers pivoted away from compounded GLP-1s following that settlement and shifted focus to branded medications. The legal and regulatory picture for compounded semaglutide broadly has been shifting since early 2026, so any platform still offering it is worth scrutinizing carefully for current compliance status before ordering.
What does a 503A compounding designation actually mean, and why does it come up so often in this comparison?
A 503A pharmacy compounds medications for individual patients under a valid prescription. It operates under state board oversight and must follow USP standards, including USP-797 for sterile preparations. It is not the same as a manufacturer. The designation matters here because it is the legal framework under which most compounded GLP-1 telehealth medications are dispensed, and knowing whether a platform uses a named, verified 503A facility is one of the few concrete quality checks available to patients.
Sources
- SURMOUNT-1 tirzepatide trial results, published in *The New England Journal of Medicine*, 2022
- STEP 1 semaglutide trial results, published in *The New England Journal of Medicine*, 2021
- FDA warning letters to compounding telehealth firms, FDA.gov, January-March 2026
- Novo Nordisk settlement announcement regarding compounded semaglutide, March 9, 2026
- LillyDirect orforglipron launch coverage, Fierce Pharma and STAT News, April 2026
- LegitScript certification database, LegitScript.com
